ACH
RNAM

ArrowMark Colorado Holdings’s Avidity Biosciences RNAM Stock Holding History

ArrowMark Colorado Holdings’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-78,842
Closed -$2.22M – 351
2020
Q3 		$2.22M Sell
78,842
-121,158
-61% -$3.5M 0.02% 253
2020
Q2 		$5.65M Buy
+200,000
New +$5.77M 0.06% 185

Other funds holding RNAM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

ArrowMark Colorado Holdings's RNAM Position: Q4 2020 in Review

ArrowMark Colorado Holdings sold out of Avidity Biosciences (RNAM) in Q4 2020, closing a stake of 78,842 shares — an estimated $2.22M sold.

ArrowMark Colorado Holdings first reported a position in RNAM in Q2 2020 and held it in 2 quarters. The position peaked at $5.65M in Q2 2020. 82 funds tracked by Wall St. Rank hold RNAM as of Q4 2020.

  • ArrowMark Colorado Holdings reported no remaining Avidity Biosciences position as of Q4 2020 after selling out during the quarter.
  • ArrowMark Colorado Holdings sold 78,842 Avidity Biosciences shares in Q4 2020, an estimated $2.22M.
  • ArrowMark Colorado Holdings first reported a position in Avidity Biosciences in Q2 2020 and held it in 2 quarters.
  • ArrowMark Colorado Holdings's Avidity Biosciences position peaked at $5.65M in Q2 2020.
  • 82 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2020.

Based on ArrowMark Colorado Holdings's 13F filing for Q4 2020, filed 16 Feb 2021.